Unacylated tridecaptin A1 acts as an effective sensitiser of Gram-negative bacteria to other antibiotics

被引:30
作者
Cochrane, Stephen A. [1 ]
Vederas, John C. [1 ]
机构
[1] Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Tridecaptin; Lipopeptide; Antibiotic; Gram-negative bacteria; Rifampicin; Vancomycin; POLYMYXIN DERIVATIVE NAB739; 3 POSITIVE CHARGES; ANTIMICROBIAL ACTIVITY; KLEBSIELLA-PNEUMONIAE; INSIGHTS; MODE;
D O I
10.1016/j.ijantimicag.2014.08.008
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A derivative of the linear cationic lipopeptide tridecaptin A(1) missing the N-terminal lipophilic acyl group, termed H-TriA(1), is devoid of antimicrobial activity but is extremely effective at sensitising Gram-negative bacteria to certain antibiotics. H-TriA(1) has low cytotoxicity compared with the natural peptide and in low concentrations it can substantially lower the minimum inhibitory concentration (MIC) of some antibiotics against strains of Escherichia coli, Campylobacter jejuni and Klebsiella pneumoniae. In particular, the MIC of rifampicin was lowered 256-512-fold against K. pneumoniae strains using low concentrations of H-TriA(1). H-TriA(1) does not exert its synergistic effect through partial membrane lysis, but does bind to model bacterial membranes in a manner akin to the natural peptide. Formation of this stable secondary structure on the outer membrane may account for the observed synergistic activity. (C) 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:493 / 499
页数:7
相关论文
共 30 条
  • [1] Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies
    Bonelli, RR
    Schneider, T
    Sahl, HG
    Wiedemann, I
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) : 1449 - 1457
  • [2] Antibiotics in the clinical pipeline in 2013
    Butler, Mark S.
    Blaskovich, Mark A.
    Cooper, Matthew A.
    [J]. JOURNAL OF ANTIBIOTICS, 2013, 66 (10) : 571 - 591
  • [3] LIPOTEICHOIC ACID AS A NEW TARGET FOR ACTIVITY OF ANTIBIOTICS - MODE OF ACTION OF DAPTOMYCIN (LY146032)
    CANEPARI, P
    BOARETTI, M
    LLEO, MD
    SATTA, G
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) : 1220 - 1226
  • [4] Canton R., Clinical Microbiology and Infection
  • [5] Cochrane S. A., 2014, MED RES REV
  • [6] Key Residues in Octyl-Tridecaptin A1 Analogues Linked to Stable Secondary Structures in the Membrane
    Cochrane, Stephen A.
    Findlay, Brandon
    Vederas, John C.
    Ratemi, Elaref S.
    [J]. CHEMBIOCHEM, 2014, 15 (09) : 1295 - 1299
  • [7] Synthesis and Structure-Activity Relationship Studies of N-Terminal Analogues of the Antimicrobial Peptide Tridecaptin A1
    Cochrane, Stephen A.
    Lohans, Christopher T.
    Brandelli, Jeremy R.
    Mulvey, George
    Armstrong, Glen D.
    Vederas, John C.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (03) : 1127 - 1131
  • [8] Risk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae
    Gasink, Leanne B.
    Edelstein, Paul H.
    Lautenbach, Ebbing
    Synnestvedt, Marie
    Fishman, Neil O.
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2009, 30 (12) : 1180 - 1185
  • [9] NISIN AS A MODEL FOOD PRESERVATIVE
    HANSEN, JN
    [J]. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 1994, 34 (01) : 69 - 93
  • [10] Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii
    Karah, Nabil
    Sundsfjord, Arnfinn
    Towner, Kevin
    Samuelsen, Orjan
    [J]. DRUG RESISTANCE UPDATES, 2012, 15 (04) : 237 - 247